EGFR and KRAS mutations and altered c-Met gene copy numbers in primary non-small cell lung cancer and associated stage N2 lymph node-metastasis

Cancer Letters

Volumn 314, Issue 1, 2012, Pages 63-72

  Han, Cheng Bo ^a   Ma, Jie Tao ^a   Li, Fan ^a   Zhao, Jian Zhu ^a   Jing, Wei ^a   Zhou, Yang ^a   Zou, Hua Wei ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Epidermal growth factor receptor; Gene copy number; KRAS; MET; Mutation; Non small cell lung cancer

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; GENOMIC DNA; K RAS PROTEIN; SCATTER FACTOR RECEPTOR;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; C MET GENE; CANCER RADIOTHERAPY; CANCER STAGING; CIGARETTE SMOKING; CLINICAL ARTICLE; CONTROLLED STUDY; COPY NUMBER VARIATION; DISEASE FREE SURVIVAL; DNA ISOLATION; EGFR GENE; FEMALE; GENE; GENE MUTATION; GENETIC ASSOCIATION; GENOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KRAS GENE; LUNG NON SMALL CELL CANCER; LUNG RESECTION; LYMPH NODE METASTASIS; MALE; MUTATIONAL ANALYSIS; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENE DOSAGE; GENES, ERBB-1; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MET; RAS PROTEINS;

EID: 82355191770     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.09.012     Document Type: Article

References (33)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics 2009. CA Cancer J. Clin. 2009, 59(2009):225-249.
2. Garnis C., Lockwood W.W., Vucic E., Ge Y., Girard L., Minna J.D., Gazdar A.F., Lam S., MacAulay C., Lam W.L. High resolution analysis of nonsmall cell lung cancer cell lines by whole genome tiling path array CGH. Int. J. Cancer 2006, 118:1556-1564.
3. Mounawar M., Mukeria A., Le Calvez F., Hung R.J., Renard H., Cortot A., Bollart C., Zaridze D., Brennan P., Boffetta P., Brambilla E., Hainaut P. Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in non-small cell lung cancers in relation to smoking history. Cancer Res. 2007, 67:5667-5672.
4. Mok T.S., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., Saijo N., Sunpaweravong P., Han B., Margono B., Ichinose Y., Nishiwaki Y., Ohe Y., Yang J.J., Chewaskulyong B., Jiang H., Duffield E.L., Watkins C.L., Armour A.A., Fukuoka M. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 2009, 361:947-957.
5. Maemondo M., Inoue A., Kobayashi K., Sugawara S., Oizumi S., Isobe H., Gemma A., Harada M., Yoshizawa H., Kinoshita I., Fujita Y., Okinaga S., Hirano H., Yoshimori K., Harada T., Ogura T., Ando M., Miyazawa H., Tanaka T., Saijo Y., Hagiwara K., Morita S., Nukiwa T. North-East Japan study group, North-East Japan study group. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N. Engl. J. Med. 2010, 362:2380-2388.
6. Massarelli E., Varella-Garcia M., Tang X., Xavier A., Ozburn N., Liu D., Bekele B., Herbst R., Wistuba I. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin. Cancer Res. 2007, 13:2890-2896.
7. Linardou H., Dahabreh I.J., Kanaloupiti D., Siannis F., Bafaloukos D., Kosmidis P., Papadimitriou C.A., Murray S. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol. 2008, 9:962-972.
8. Tsao M.S., Zhu C., Sakurada A. An analysis of the prognostic and predictive importance of predictive importance of K-ras mutation status in the National Cancer Institute of Canada Clinical Trials Group BR.21 study of erlotinib versus placebo in the treatment of non-small cell lung cancer. J. Clin. Oncol. 2006, 24:18S.
9. Gazdar A.F. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene 2009, 28(Suppl 1):S24-31.
10. Ogino A., Kitao H., Hirano S., Uchida A., Ishiai M., Kozuki T., Takigawa N., Takata M., Kiura K., Tanimoto M. Emergence of epidermal growth factor receptor T790M mutation during chronic exposure to gefitinib in a nonsmall cell lung cancer cell line. Cancer Res. 2007, 67:7807-7814.
11. Maheswaran S., Sequist L.V., Nagrath S., Ulkus L., Brannigan B., Collura C.V., Inserra E., Diederichs S., Iafrate A.J., Bell D.W., Digumarthy S., Muzikansky A., Irimia D., Settleman J., Tompkins R.G., Lynch T.J., Toner M., Haber D.A. Detection of mutations in EGFR in circulating lung-cancer cells. N. Engl. J. Med. 2008, 359:366-377.
12. Toschi L., Cappuzzo F. Clinical implications of MET gene copy number in lung cancer. Future Oncol. 2010, 6:239-247.
13. Bean J., Brennan C., Shih J.Y., Riely G., Viale A., Wang L., Chitale D., Motoi N., Szoke J., Broderick S., Balak M., Chang W.C., Yu C.J., Gazdar A., Pass H., Rusch V., Gerald W., Huang S.F., Yang P.C., Miller V., Ladanyi M., Yang C.H., Pao W. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc. Natl. Acad. Sci. USA 2007, 104:20932-20937.
14. Paez J.G., Jänne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., Herman P., Kaye F.J., Lindeman N., Boggon T.J., Naoki K., Sasaki H., Fujii Y., Eck M.J., Sellers W.R., Johnson B.E., Meyerson M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
15. Spremulli E.N., Dexter D.L. Human tumor cell heterogeneity and metastasis. J. Clin. Oncol. 1983, 1:496-509.
16. Schmid K., Oehl N., Wrba F., Pirker R., Pirker C., Filipits M. EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases. Clin. Cancer Res. 2009, 15:4554-4560.
17. Gomez-Roca C., Raynaud C.M., Penault-Llorca F., Mercier O., Commo F., Morat L., Sabatier L., Dartevelle P., Taranchon E., Besse B., Validire P., Italiano A., Soria J.C. Differential expression of biomarkers in primary non-small cell lung cancer and metastatic sites. J. Thorac. Oncol. 2009, 4:1212-1220.
18. Matsumoto S., Takahashi K., Iwakawa R., Matsuno Y., Nakanishi Y., Kohno T., Shimizu E., Yokota J. Frequent EGFR mutations in brain metastases of lung adenocarcinoma. Int. J. Cancer 2006, 119:1491-1494.
19. Gow C.H., Chang Y.L., Hsu Y.C., Tsai M.F., Wu C.T., Yu C.J., Yang C.H., Lee Y.C., Yang P.C., Shih J.Y. Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer. Ann. Oncol. 2009, 20:696-702.
20. Park S., Holmes-Tisch A.J., Cho E.Y., Shim Y.M., Kim J., Kim H.S., Lee J., Park Y.H., Ahn J.S., Park K., Jänne P.A., Ahn M.J. Discordance of molecular biomarkers associated with epidermal growth factor receptor pathway between primary tumors and lymph node metastasis in non-small cell lung cancer. J. Thorac. Oncol. 2009, 4:809-815.
21. Daniele L., Cassoni P., Bacillo E., Cappia S., Righi L., Volante M., Tondat F., Inghirami G., Sapino A., Scagliotti G.V., Papotti M., Novello S. Epidermal growth factor receptor gene in primary tumor and metastatic sites from non-small cell lung cancer. J. Thorac. Oncol. 2009, 4:684-688.
22. Cortot A.B., Italiano A., Burel-Vandenbos F., Martel-Planche G., Hainaut P. KRAS mutation status in primary nonsmall cell lung cancer and matched metastases. Cancer 2010, 116:2682-2687.
23. Han C., Zou H., Ma J., Zhou Y., Zhao J. Comparison of EGFR and KRAS status between primary non-small cell lung cancer and corresponding metastases: a systematic review and meta-analysis. Zhongguo Fei Ai Za Zhi 2010, 13:882-891.
24. Kalikaki A., Koutsopoulos A., Trypaki M., Souglakos J., Stathopoulos E., Georgoulias V., Mavroudis D., Voutsina A. Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC. Br. J. Cancer 2008, 99:923-929.
25. Badalian G., Barbai T., Rásó E., Derecskei K., Szendrôi M., Tímár J. Phenotype of bone metastases of non-small cell lung cancer: epidermal growth factor receptor expression and K-RAS mutational status. Pathol. Oncol. Res. 2007, 13:99-104.
26. Monaco S.E., Nikiforova M.N., Cieply K., Teot L.A., Khalbuss W.E., Dacic S. A comparison of EGFR and KRAS status in primary lung carcinoma and matched metastases. Human Pathol. 2010, 41:94-102.
27. Takahashi K., Kohno T., Matsumoto S., Nakanishi Y., Arai Y., Fujiwara T., Tanaka N., Yokota J. Clonality and heterogeneity of pulmonary blastoma from the viewpoint of genetic alterations: a case report. Lung cancer 2007, 57:103-108.
28. Kuukasjärvi T., Karhu R., Tanner M., Kähkönen M., Schäffer A., Nupponen N., Pennanen S., Kallioniemi A., Kallioniemi O.P., Isola J. Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer. Cancer Res. 1997, 57:1597-1604.
29. Marchetti A., Milella M., Felicioni L., Cappuzzo F., Irtelli L., Del Grammastro M., Sciarrotta M., Malatesta S., Nuzzo C., Finocchiaro G., Perrucci B., Carlone D., Gelibter A.J., Ceribelli A., Mezzetti A., Iacobelli S., Cognetti F., Buttitta F. Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones. Neoplasia 2009, 11:1084-1092.
30. Nguyen K.S., Kobayashi S., Costa D.B. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin. Cancer Res. 2009, 10:281-289.
31. Engelman J.A., Zejnullahu K., Mitsudomi T., Song Y., Hyland C., Park J.Q., Lindeman N., Gale C.M., Zhao X., Christensen J., Kosaka T., Holmes A.J., Rogers A.M., Cappuzzo F., Mok T., Lee C., Johnson B.E., Cantley L.C., Jänne P.A. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316:1039-1043.
32. Turke A.B., Zejnullahu K., Wu Y.L., Song Y., Dias-Santagata D., Lifshits E., Toschi L., Rogers A., Mok T., Sequist L., Lindeman N.I., Murphy C., Akhavanfard S., Yeap B.Y., Xiao Y., Capelletti M., Iafrate A.J., Lee C., Christensen J.Q., Engelman J.A., Jänne P.A. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 2010, 17:77-88.
33. Cappuzzo F., Marchetti A., Skokan M., Rossi E., Gajapathy S., Felicioni L., Del Grammastro M., Sciarrotta M.G., Buttitta F., Incarbone M., Toschi L., Finocchiaro G., Destro A., Terracciano L., Roncalli M., Alloisio M., Santoro A., Varella-Garcia M. Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J. Clin. Oncol. 2009, 27:1667-1674.